Millennium Provides Update On SNDA For VELCADE In Relapsed Follicular Lymphoma
10/08/2011
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) announced that it is withdrawing the supplemental new drug application (sNDA) for the use of VELCADE® (bortezomib) for Injection in combination with rituximab in patients with relapsed follicular lymphoma...
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Cialis® (tadalafil) tablets for once daily use for the treatment of men who have both erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (ED+BPH)...
FDA Approves Cialis To Treat Benign Prostatic Hyperplasia
10/08/2011
The U.S. Food and Drug Administration today approved Cialis (tadalafil) to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a condition in which the prostate gland becomes enlarged, and for the treatment of BPH and erectile dysfunction (ED), when the conditions occur simultaneously. Cialis was approved in 2003 for the treatment of ED...
Millennium Provides Update On SNDA For VELCADE In Relapsed Follicular Lymphoma
10/08/2011
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) announced that it is withdrawing the supplemental new drug application (sNDA) for the use of VELCADE® (bortezomib) for Injection in combination with rituximab in patients with relapsed follicular lymphoma...
Male Breast Cancer Survival Rates Better Than Women's
10/08/2011
Not only is male breast cancer much rarer than female breast cancer, researchers from the National University of Singapore found that men who develop breast cancer also have a lower risk of death, even though they are more likely to have advanced disease. Their findings have been published in the Journal of Clinical Oncology...
UCSD Experts Respond To New Guidelines For Prostate Cancer Test
10/08/2011
Yesterday, the United States Preventive Services Task Force released a draft recommendation that states healthy men should no longer receive a P.S.A test for prostate cancer as it often leads to unnecessary testing and procedures and does not save lives...
UNC Researcher To Help Lead New Esophageal Cancer Network
10/08/2011
A University of North Carolina at Chapel Hill researcher is one of five co-principal investigators in a new collaborative network created to study genetic determinants of Barrett's esophagus and esophageal adenocarcinoma. Nicholas J...
Male Breast Cancer Survival Rates Better Than Women's
10/07/2011
Not only is male breast cancer much rarer than female breast cancer, researchers from the National University of Singapore found that men who develop breast cancer also have a lower risk of death, even though they are more likely to have advanced disease. Their findings have been published in the Journal of Clinical Oncology...
Drop Routine PSA Test For Prostate Cancer Says US Panel
10/07/2011
Reports are coming in that an expert panel that advises the US government is set to recommend dropping routine screening for prostate cancer using the prostate specific antigen, or PSA, test...
Resectability With Cetuximab Extends Life In Difficult-to-Treat Metastatic Colorectal Cancer
10/07/2011
Combining the epidermal growth factor receptor (EGFR) inhibitor cetuximab with conventional chemotherapy improves survival in patients who have had complete resection of colorectal liver metastases that were initially judged to be unresectable, according to data presented at the 2011 European Multidisciplinary Cancer Congress (EMCC)...